References
- PragerWDifferential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown linesClin Pharmacol20135395223516136
- PickettAImmunogenicity issues related to botulinum toxins in clinical use cannot be answered by speculation about product characteristicsBioDrugs2013271838423329399
- EiseleK-HFinkKVeyMTaylorHVStudies on the dissociation of botulinum neurotoxin type A complexesToxicon201157455556521195107
- PragerWHuber-VorlanderJTaufigAZBotulinum toxin type A treatment to the upper face: retrospective analysis of daily practiceClin Cosmet Investig Dermatol201255358
- PickettACairdDComparison of type a botulinum toxin products in clinical useJ Clin Pharm Ther200833332732818452421
- PickettAInability of speculation to explain dose effect differences between botulinum toxin productsArch Facial Plast Surg201214646746823165908
References
- PragerWDifferential characteristics of incobotulinumtoxinA and its use in the management of glabellar frown linesClin Pharmacol20135395223516136
- EiseleK-HFinkKVeyMTaylorHVStudies on the dissociation of botulinum neurotoxin type A complexesToxicon201157455556521195107
- JankovicJVuongKDAhsanJComparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystoniaNeurology20036071186118812682332
- PickettAImmunogenicity issues related to botulinum toxins in clinical use cannot be answered by speculation about product characteristicsBioDrugs2013271838423329399
- LeeJCYokotaKArimitsuHProduction of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutininMicrobiology112005151Pt 113739374716272395
- FrevertJContent of botulinum neurotoxin in Botox®/Vistabel®, Dysport®/Azzalure®, and Xeomin®/Bocouture®Drugs R D2010102677320698714
- Azzalure®. [summary of product characteristics]Galderma (UK) LtdHertfordshire, UK2010
- GreinSMGFinkKStability of botulinum neurotoxin type A, devoid of complexing proteinsThe Botulinum Journal2011214958